title: Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat.
abstract: Changes in striatal dopamine uptake sites, D2 receptor and preproenkephalin (PPE) mRNA levels provoked by unilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopaminergic (DA) pathway were studied by quantitative autoradiography and in situ hybridization (ISH) in rats sacrificed at different post-lesion delays. The disappearance of DA terminals as visualized with the labelling of dopamine uptake sites with [3H]GBR 12935 became significant 36 h after the lesion and was almost complete at a delay of 7 days. PPE mRNA amounts significantly increase (+24%) already at the shortest delay studied (9 h after the lesion) while the labelling of the uptake sites on DA terminals was not affected. The time course increase of PPE mRNA levels was progressive until 21 days post-lesion where it reached its maximum (+132%) and remained stable up to the latest delay studied (60 days). Conversely D2 mRNA contents remained unchanged up to 5 days post-surgery and then increased relatively quickly since at 7 days post-lesion their levels were near (+21%) the maximum observed which was reached at 21 days post-lesion (+32%). This study suggests a time-dependent differential sensitivity to the degree of DA denervation of both major components implicated in the striatopallidal output.
authors.affiliation: INSERM U.318, LAPSEN, Département des Neurosciences Cliniques et Biologiques, CHU de Grenoble, France.
authors.forename: M
authors.initials: M
authors.lastname: Chritin
authors.forename: C
authors.initials: C
authors.lastname: Feuerstein
authors.forename: M
authors.initials: M
authors.lastname: Savasta
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001692:Biological Transport; D003342:Corpus Striatum / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D004298:Dopamine / Q000378:metabolism*; D004745:Enkephalins / Q000096:biosynthesis*; D017403:In Situ Hybridization; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D016627:Oxidopamine / Q000008:administration & dosage; D010879:Piperazines / Q000378:metabolism; D011498:Protein Precursors / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000096:biosynthesis*; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D013997:Time Factors
chemical_list: D004745:Enkephalins; D010879:Piperazines; D011498:Protein Precursors; D012333:RNA, Messenger; D017448:Receptors, Dopamine D2; D016627:Oxidopamine; C033660:preproenkephalin; C044630:1-(2 (diphenylmethoxy)ethyl)-4-(3-phenylpropyl)piperazine; D001058:Apomorphine; D004298:Dopamine